Skip to main content
Clinical Trials/NCT02247622
NCT02247622UnknownNot Applicable

Primary Sclerosing Cholangitis Telomere Length

Meir Medical Center1 site in 1 country60 target enrollmentStarted: February 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
60
Locations
1
Primary Endpoint
Telomere length

Study Overview

Brief Summary

PSC is a chronic cholestatic disorder. The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.

Detailed Description

Primary sclerosing cholangitis (PSC) and colitis are chronic inflammatory disorders with malignant potential. Telomerase is an enzyme complex that lengthens telomeres and has enhanced expression in numerous malignancies. In this study, we evaluated the telomerase gene copy number, telomere length, cells in senescence, aneuploidy and additional parameters of telomere dysfunction from peripheral blood lymphocytes of patients.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •informed consent
  • •documented PSC and inflammatory bowel disease

Exclusion Criteria

  • •under 18 years, above 80 y
  • •known active malignancy
  • •decompensated cirrhosis
  • •patients who cannot sign informed consent

Outcomes

Primary Outcomes

Telomere length

Time Frame: 1.5 years

Secondary Outcomes

  • number of cells with increased telomerase RNA component (TERC) expression(1.5 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

ido laish

Md.

Meir Medical Center

Study Sites (1)

Loading locations...

Similar Trials